Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma. - Wikidata - wikimedia - TriplyDB

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

http://www.wikidata.org/entity/Q35321868

about

Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.

P2860

Q28066935-BBAC9C20-9992-42B3-871C-F65E77ACE5A8 Q33909086-01B4AC50-25EC-45B0-9B38-5598F10B80E5 Q36105149-AB367A39-DF5A-4140-8C09-1B837A2A9DDD Q36127898-0511D185-9990-489D-8F26-5BF2405BCECA Q37327294-731A9F72-835D-4425-85DD-9FD07E3DD717 Q42660155-18BFE66B-568E-4FE3-BC0F-FE31A6598A31 Q44645655-2D67C376-3648-4DBC-8F43-002F1C27A053

P2860

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

http://www.wikidata.org/entity/Q35321868

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

@ast

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

@en

type

label

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

@ast

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

@en

prefLabel

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

@ast

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

@en

P1433

Q35321868-182B5C92-82E8-4601-8861-BDF0DE825C21

P1476

Q35321868-D92C1F8D-1086-4D1C-ABDD-406D8F53411E

P2093

Q35321868-0AB9D4C2-90B3-4DD6-91FE-DA82AB03E946

Q35321868-94A0EEBC-B3C1-44B9-8ABF-2491A6A91B12

Q35321868-9D29231D-4C39-4071-92F1-4B449B320B46

Q35321868-9EC8A2A6-4A15-473F-9745-DC36C7027337

Q35321868-A41DF1C3-1A8C-42E1-B5EE-56B765292AF9

Q35321868-B074622A-FA5D-487C-AC1A-224C091EE6F3

Q35321868-CA29D785-A4F4-4907-97CB-1C7446967519

Q35321868-DEA200F0-16F1-4722-A592-8C8F85385623

P2860

Q35321868-0566FF8D-DD64-4213-8C51-62740CFBEAE8

Q35321868-0EABDA1E-2ABF-4D92-96AE-BFBA2D8DAC53

Q35321868-10B7D7CC-12E1-43E0-875E-503086D43E8A

Q35321868-17EAA0B0-605A-4431-808E-CF73D9855637

Q35321868-1DB926E3-1E56-48DC-A8CA-8C2C45624BAB

Q35321868-2409A492-3CDB-4BC0-A2E1-C278FBD31423

Q35321868-2EC12920-0F7B-42E3-8D09-28403B6B9B79

Q35321868-3333410C-797E-4025-AA29-9CBD974A1DBB

Q35321868-3410EADE-66D1-4C16-BA82-AEEB94A7058A

Q35321868-35BCCD23-CBDA-4674-93D7-F29592F004DF

P304

Q35321868-1A893596-9CDD-464D-83C3-E28714931F18

P31

Q35321868-10BD9BE1-C489-4503-A9C9-5004D33A8A4A

P356

Q35321868-16D17A55-C39F-4B33-ABAC-5629620B87CA

P433

Q35321868-0F79DDA1-8B22-498B-A086-5676082D9EE1

P478

Q35321868-5EE09B94-3AC0-42B1-805E-8D287C05CEA4

P577

Q35321868-B02ED8CF-2DDD-4042-B275-D28BD67E9FE4

P698

Q35321868-6504D639-AAA6-491F-BC3C-BF95030A4F5D

P932

Q35321868-905C9F27-65C6-481B-8EBB-B8A905E7A598

P356

P1433

Journal of Interferon and Cytokine Research

P1476

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

@en

P2093

Alan Lichtenstein

http://www.w3.org/2001/XMLSchema#string

Alex Vasuthasawat

http://www.w3.org/2001/XMLSchema#string

Bao Hoang

http://www.w3.org/2001/XMLSchema#string

Danh Tran

http://www.w3.org/2001/XMLSchema#string

Esther M Yoo

http://www.w3.org/2001/XMLSchema#string

Juan Zhang

http://www.w3.org/2001/XMLSchema#string

Kham R Trinh

http://www.w3.org/2001/XMLSchema#string

Sherie L Morrison

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of Interferon-alpha induced apoptosis in malignant cells

Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma

Interferons at age 50: past, current and future impact on biomedicine

An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.

Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.

NOD-scid IL2rgamma(null) mouse model of human skin transplantation and allograft rejection

Second-generation interferons for cancer: clinical targets.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

P304

281-291

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/JIR.2014.0125

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25353626

http://www.w3.org/2001/XMLSchema#string

P932

4390003

http://www.w3.org/2001/XMLSchema#string